Alma, Hanka and Šárka are taking a bio-break from the group to devote their time to an enriching activity that each of us have participated in in some form at least once. We took the liberty to wish you well. It was great working with you and we are looking forward to continue and have you back at some point! You are very welcome to pop in for a coffee or a chat any time before that!
Anežka Tichá leaves the group after seven great years as a PhD student and postdoc. Anežka was absolutely key for the development of the ketoamide inhibitors of rhomboid proteases. We all greatly enjoyed having her as a colleague and friend. You will be sorely missed in the lab. Others will enjoy your presence, at Janssen. :)
Keep in touch and best of luck!
We have contributed to a collaborative paper with the Adrain, Domingos and Christianson groups that identifies new clients of the EMC complex and reveals an EMC dependent biogenesis factor of rhodopsin. Just published early view in the EMBO Reports. What a pleasurable collaboration!
We have contributed to a collaborative paper with the Freeman lab that reveals the role of the rhomboid intramembrane protease RHBDL2 in calcium signalling and conformational quality control in T-cells. Just published in Molecular Cell.
There is more from us on RHBDL2 in the pipeline... Watch this space!
Check out how faulty proteins are extracted across the membranes of cellular organelles to be degraded by the proteasome in the cytosol. Summarised in a hot-off-the-press review by Kvido Strisovsky and Marius Lemberg in Molecular Cell.
Mgr. Hana Dvořáková has worked in parasitology at Charles University, and now joins our group at IOCB as a research assistant. Welcome!
Best of luck!
Our collaboration with the former Urban laboratory over the last few years has yielded this article in Cell Chemical Biology, which shows that pharmacological targetting of Plasmodium falciparum rhomboid proteases by ketoamides is feasible. Inhibition of PfROM4 blocks the entry of the parasite into the host cells and cures the culture, hence establishing Plasmodium rhomboids as new drug targets.